Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

This study has been completed.
Sponsor:
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Information provided by (Responsible Party):
Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00312845
First received: April 7, 2006
Last updated: June 19, 2012
Last verified: June 2012
Results First Received: June 29, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Bortezomib + Rituximab
Drug: Rituximab

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Bortezomib + Rituximab 1.6 mg/m^2 VELCADE for Injection administered weekly on Days 1, 8, 15, and 22 of a 35-day cycle in combination with 4 doses of 375 mg/m^2 rituximab once weekly on Days 1, 8, 15, and 22 of Cycle 1 and a single dose of 375 mg/m^2 rituximab on Day 1 of Cycles 2 through 5 (for a total of 8 doses of rituximab).
Rituximab 375 mg/m^2 rituximab once weekly on Days 1, 8, 15, and 22 of Cycle 1, and as a single dose of 375 mg/m^2 on Day 1 of Cycles 2 through 5 (for a total of 8 doses).

Participant Flow:   Overall Study
    Bortezomib + Rituximab     Rituximab  
STARTED     336     340  
COMPLETED     237     245  
NOT COMPLETED     99     95  
Adverse Event                 19                 5  
Death                 2                 2  
Withdrawal by Subject                 14                 6  
Disease Progression                 56                 77  
Lost to Follow-up                 2                 0  
Other                 6                 5  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Bortezomib + Rituximab 1.6 mg/m^2 VELCADE for Injection administered weekly on Days 1, 8, 15, and 22 of a 35-day cycle in combination with 4 doses of 375 mg/m^2 rituximab once weekly on Days 1, 8, 15, and 22 of Cycle 1 and a single dose of 375 mg/m^2 rituximab on Day 1 of Cycles 2 through 5 (for a total of 8 doses of rituximab).
Rituximab 375 mg/m^2 rituximab once weekly on Days 1, 8, 15, and 22 of Cycle 1, and as a single dose of 375 mg/m^2 on Day 1 of Cycles 2 through 5 (for a total of 8 doses).
Total Total of all reporting groups

Baseline Measures
    Bortezomib + Rituximab     Rituximab     Total  
Number of Participants  
[units: participants]
  336     340     676  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     243     242     485  
>=65 years     93     98     191  
Age  
[units: years]
Mean ± Standard Deviation
  56.8  ± 11.12     57.3  ± 12     57  ± 11.56  
Gender  
[units: participants]
     
Female     164     203     367  
Male     172     137     309  
Region of Enrollment  
[units: participants]
     
United States     14     16     30  
Portugal     11     12     23  
Slovakia     7     8     15  
Greece     1     1     2  
Thailand     2     1     3  
Spain     9     5     14  
Ukraine     13     11     24  
Israel     7     7     14  
Russian Federation     52     55     107  
Italy     14     15     29  
India     17     24     41  
France     13     10     23  
Australia     5     3     8  
South Africa     2     2     4  
China     46     40     86  
Korea, Republic of     4     3     7  
Finland     1     2     3  
United Kingdom     9     10     19  
Hungary     3     6     9  
Czech Republic     18     17     35  
Mexico     9     8     17  
Canada     9     10     19  
Argentina     2     5     7  
Brazil     18     21     39  
Belgium     18     19     37  
Poland     24     21     45  
Romania     6     2     8  
Germany     0     3     3  
Sweden     2     3     5  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Progression Free Survival   [ Time Frame: Subjects are followed until progressive disease/death or the end of the study. The median follow up time is 33.9 months. ]

2.  Secondary:   Overall Response Rate   [ Time Frame: Subjects are followed until progressive disease/death or the end of the study. The median follow up time is 33.9 months. ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame the end of study
Additional Description No text entered.

Reporting Groups
  Description
Bortezomib + Rituximab 1.6 mg/m^2 VELCADE for Injection administered weekly on Days 1, 8, 15, and 22 of a 35-day cycle in combination with 4 doses of 375 mg/m^2 rituximab once weekly on Days 1, 8, 15, and 22 of Cycle 1 and a single dose of 375 mg/m^2 rituximab on Day 1 of Cycles 2 through 5 (for a total of 8 doses of rituximab).
Rituximab 375 mg/m^2 rituximab once weekly on Days 1, 8, 15, and 22 of Cycle 1, and as a single dose of 375 mg/m^2 on Day 1 of Cycles 2 through 5 (for a total of 8 doses).

Serious Adverse Events
    Bortezomib + Rituximab     Rituximab  
Total, serious adverse events      
# participants affected / at risk     59/334 (17.66%)     37/339 (10.91%)  
Blood and lymphatic system disorders      
Febrile neutropenia † 1    
# participants affected / at risk     5/334 (1.50%)     3/339 (0.88%)  
Neutropenia † 1    
# participants affected / at risk     2/334 (0.60%)     2/339 (0.59%)  
Bone marrow failure † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Leukopenia † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Anaemia † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Lymphadenopathy † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Cardiac disorders      
Left entricular dysfunction † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Palpitations † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Pericardial effusion † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Right ventricular dysfunction † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Acute myocardial infarction † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Angina unstable † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Cardiac failure acute † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Cardiogenic shock † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Coronary artery disease † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Cyanosis † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Tachycardia † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Gastrointestinal disorders      
Diarrhoea † 1    
# participants affected / at risk     5/334 (1.50%)     2/339 (0.59%)  
Vomiting † 1    
# participants affected / at risk     4/334 (1.20%)     1/339 (0.29%)  
Abdominal pain † 1    
# participants affected / at risk     2/334 (0.60%)     2/339 (0.59%)  
Colonic obstruction † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Enteritis † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Gastrointestinal obstruction † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Constipation † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Dysphagia † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Nausea † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Periodontitis † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Toothache † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
General disorders      
Pyrexia † 1    
# participants affected / at risk     6/334 (1.80%)     2/339 (0.59%)  
Asthenia † 1    
# participants affected / at risk     1/334 (0.30%)     2/339 (0.59%)  
Chest pain † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Oedema peripheral † 1    
# participants affected / at risk     1/334 (0.30%)     1/339 (0.29%)  
Pain † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Chest discomfort † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Hepatobiliary disorders      
Cholangitis acute † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Cholecystitis acute † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Cirrhosis alcoholic † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Immune system disorders      
Hypersensitivity † 1    
# participants affected / at risk     4/334 (1.20%)     1/339 (0.29%)  
Anaphylactic reaction † 1    
# participants affected / at risk     2/334 (0.60%)     0/339 (0.00%)  
Infections and infestations      
Pneumonia † 1    
# participants affected / at risk     7/334 (2.10%)     3/339 (0.88%)  
Herpes zoster † 1    
# participants affected / at risk     4/334 (1.20%)     0/339 (0.00%)  
Sepsis † 1    
# participants affected / at risk     3/334 (0.90%)     0/339 (0.00%)  
Urinary tract infection † 1    
# participants affected / at risk     0/334 (0.00%)     2/339 (0.59%)  
Bronchopneumonia † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Clostridial infection † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Empyema † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Laryngitis † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Lower respiratory tract infection † 1    
# participants affected / at risk     1/334 (0.30%)     1/339 (0.29%)  
Meningitis † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Necrotixing fasciitis † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Pharyngitis † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Tracheobronchitis † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Aspergillosis † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Gastroenteritis salmonella † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Hepatitis B † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Hepatitis viral † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Herpes virus infection † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Pyelonephritis † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Respiratory tract infection † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Septic shock † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Upper respiratory tract infection † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Injury, poisoning and procedural complications      
Collapse of lung † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Concussion † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Pelvic fracture † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Upper limb fracture † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Metabolism and nutrition disorders      
Dehydration † 1    
# participants affected / at risk     2/334 (0.60%)     0/339 (0.00%)  
Decreased appetite † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Hyperglycaemia † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Hyperkalaemia † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Hyponatraemia † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Musculoskeletal and connective tissue disorders      
Arthralgia † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Neoplasms benign, malignant and unspecified (incl cysts and polyps)      
Benign breast neoplasm † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Tumour necrosis † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Rectal cancer † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Nervous system disorders      
Cerebrovascular accident † 1    
# participants affected / at risk     2/334 (0.60%)     0/339 (0.00%)  
Convulsion † 1    
# participants affected / at risk     1/334 (0.30%)     1/339 (0.29%)  
Dementia † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Somnolence † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Loss of consciousness † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Myelopathy † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Peripheral sensory neuropathy † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Syncope † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Toxic encephalopathy † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Psychiatric disorders      
Confusional state † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Renal and urinary disorders      
Renal failure † 1    
# participants affected / at risk     2/334 (0.60%)     0/339 (0.00%)  
Calculus urinary † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Renal failure acute † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Renal impairment † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Respiratory, thoracic and mediastinal disorders      
Pleural effusion † 1    
# participants affected / at risk     2/334 (0.60%)     2/339 (0.59%)  
Hypoxia † 1    
# participants affected / at risk     2/334 (0.60%)     0/339 (0.00%)  
Chronic obstructive pulmonary disease † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Chylothorax † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Dyspnoea † 1    
# participants affected / at risk     1/334 (0.30%)     1/339 (0.29%)  
Epistaxis † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Pulmonary embolism † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Acute respiratory failure † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Pleural haemorrhage † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Pneumothorax † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Skin and subcutaneous tissue disorders      
Dermatitis allergic † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Seborrhoeic dermatitis † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Urticaria † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Hyperhidrosis † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Vascular disorders      
Hypotension † 1    
# participants affected / at risk     4/334 (1.20%)     0/339 (0.00%)  
Deep vein thrombosis † 1    
# participants affected / at risk     0/334 (0.00%)     1/339 (0.29%)  
Orthostatic hypotension † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Subclavian vein thrombosis † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Thrombosis † 1    
# participants affected / at risk     1/334 (0.30%)     0/339 (0.00%)  
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA (12.0)




  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information